Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

The DECLARE TIMI 58 trial evaluated the cardiovascular safety and efficacy of dapagliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease. The study involved 17,160 patients followed for a median of 4.2 years. Results showed that dapagliflozin was noninferior to placebo for major adverse cardiovascular events (MACE) but did not significantly reduce MACE rates. However, it significantly lowered the rate of cardiovascular death or hospitalization for heart failure, primarily due to reduced heart failure hospitalizations. Dapagliflozin also showed benefits in reducing renal composite outcomes. Safety findings included a higher incidence of diabetic ketoacidosis and genital infections with dapagliflozin, but no increased risk of amputations, fractures, or bladder cancer.

The DECLARE TIMI 58 trial evaluated the cardiovascular safety and efficacy of dapagliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease. The study involved 17,160 patients followed for a median of 4.2 years. Results showed that dapagliflozin was noninferior to placebo for major adverse cardiovascular events (MACE) but did not significantly reduce MACE rates. However, it significantly lowered the rate of cardiovascular death or hospitalization for heart failure, primarily due to reduced heart failure hospitalizations. Dapagliflozin also showed benefits in reducing renal composite outcomes. Safety findings included a higher incidence of diabetic ketoacidosis and genital infections with dapagliflozin, but no increased risk of amputations, fractures, or bladder cancer.